Advancing single-cell analysis with its proprietary PTA technology, delivering high-resolution genomic insights.

Enables breakthroughs in cancer research, genetic disorders, and personalized medicine through unmatched accuracy and coverage.

Seed Healthcare Fund is evaluating a pending investment in the upcoming Series A round in 2025.